Soleno Therapeutics Stock In The News

SLNO Stock  USD 71.99  4.60  6.83%   
Our overall analysis of Soleno Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Soleno Therapeutics. The specific impact of Soleno Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Soleno Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Soleno Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Soleno Therapeutics Backtesting and Soleno Therapeutics Hype Analysis.
To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.

Soleno Therapeutics Today Top News and Investor Outlook

Yahoo News
Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week?
https://finance.yahoo.com/news/why-soleno-therapeutics-inc-slno-023902199.html
 Neutral
Yahoo News
Why Soleno Therapeutics Inc. (SLNO) Went Up On Friday?
https://finance.yahoo.com/news/why-soleno-therapeutics-inc-slno-023021837.html
 Neutral
Yahoo News
Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday?
https://finance.yahoo.com/news/why-soleno-therapeutics-inc-slno-082559412.html
 Neutral
Macroaxis News: globenewswire.com
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome
https://www.globenewswire.com/news-release/2025/03/26/3050184/0/en/Soleno-Therapeutics-Announces-U-S-FDA-Approval-of-VYKATTM-XR-to-Treat-Hyperphagia-in-Prader-Willi-Syndrome.html
 Neutral
Macroaxis News: globenewswire.com
Soleno Therapeutics to Participate in Upcoming February Investor Conferences
https://www.globenewswire.com/news-release/2025/01/29/3017568/0/en/Soleno-Therapeutics-to-Participate-in-Upcoming-February-Investor-Conferences.html
 Bullish
Yahoo News
13 Most Promising Healthcare Stocks According to Analysts
https://finance.yahoo.com/news/13-most-promising-healthcare-stocks-164105967.html
 Bullish
Yahoo News
3 Stock Winners That Are Up 500% or More in 2023
https://finance.yahoo.com/news/3-stock-winners-500-more-120000910.html
 Bullish
Yahoo News
5 ‘Jackpot’ Stocks to Buy for 2024 for 10X Gains
https://finance.yahoo.com/news/5-jackpot-stocks-buy-2024-203821781.html
 Bullish
Yahoo News
Feeling Lucky? 5 ‘Jackpot’ Stocks to Buy for 2024.
https://finance.yahoo.com/news/feeling-lucky-5-jackpot-stocks-180232114.html
 Bullish
Yahoo News
Billionaire Seth Klarman’s Biotech Stock Picks
https://finance.yahoo.com/news/billionaire-seth-klarman-biotech-stock-141404443.html
 Bullish

Soleno Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Soleno and other traded companies coverage with news coverage. We help investors stay connected with Soleno headlines for the 30th of March to make an informed investment decision based on correlating the impacts of news items on Soleno Stock performance. Please note that trading solely based on the Soleno Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Soleno Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Soleno Therapeutics investors visualize upcoming and past events in order to time the market based on Soleno Therapeutics noise-free hype analysis.
Soleno Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Soleno earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Soleno Therapeutics that are available to investors today. That information is available publicly through Soleno media outlets and privately through word of mouth or via Soleno internal channels. However, regardless of the origin, that massive amount of Soleno data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Soleno Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Soleno Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Soleno Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Soleno Therapeutics alpha.

Soleno Largest EPS Surprises

Earnings surprises can significantly impact Soleno Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-03-06
2023-12-31-0.27-0.33-0.0622 
2022-11-09
2022-09-30-0.91-0.760.1516 
2023-05-09
2023-03-31-0.72-0.88-0.1622 
2025-03-04
2024-12-31-1.0771-1.27-0.192917 
2024-05-09
2024-03-31-0.37-0.59-0.2259 
2023-03-21
2022-12-31-0.8-0.580.2227 
View All Earnings Estimates

Soleno Therapeutics Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Soleno Therapeutics Stock. Current markets are strongly bearish. About 72% of major world exchanges and indexes are down. See today's market update for more information.
Gurufocus Stories at Macroaxis
27th of March 2025
Soleno Therapeutics Gains After FDA Approves Vykat XR for PWS
at gurufocus.com 
news
26th of March 2025
STAT Soleno life-changing rare-disease drug approved
at statnews.com 
bizjournals News
25th of March 2025
How Trumps cuts could snag a small Peninsula drug company and kids with a rare overeating ...
at bizjournals.com 
Google News at Macroaxis
21st of March 2025
Soleno Therapeutics FDA Approval May Prove To Be A Pyrrhic Victory - Seeking Alpha
at news.google.com 
news
6th of March 2025
Soleno Therapeutics Receives Buy Rating from HC Wainwright
at thelincolnianonline.com 
Yahoo News
3rd of March 2025
Exploring US High Growth Tech Stocks In March 2025
at finance.yahoo.com 
Yahoo News
27th of February 2025
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 202...
at finance.yahoo.com 
Simply Wall St News at Macroaxis
26th of February 2025
Were Hopeful That Soleno Therapeutics Will Use Its Cash Wisely
at simplywall.st 
news
5th of February 2025
Soleno Therapeutics Upgraded by Lifesci Capital to Strong-Buy Rating
at thelincolnianonline.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Soleno Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Soleno Therapeutics' short interest history, or implied volatility extrapolated from Soleno Therapeutics options trading.
When determining whether Soleno Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Soleno Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Soleno Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Soleno Therapeutics Stock:
Check out Soleno Therapeutics Backtesting and Soleno Therapeutics Hype Analysis.
To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Soleno Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.38)
Return On Assets
(0.45)
Return On Equity
(0.87)
The market value of Soleno Therapeutics is measured differently than its book value, which is the value of Soleno that is recorded on the company's balance sheet. Investors also form their own opinion of Soleno Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Soleno Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Soleno Therapeutics' market value can be influenced by many factors that don't directly affect Soleno Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Soleno Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.